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Objectives: The aim of this study is to analyze the influence of the research and
development (R&D) investment of pharmaceutical companies on enterprise
value.
Methods: The period of the empirical analysis is from 2000 to 2012, considering
the period after the influence of the financial crisis. Financial statements and
comments in general and internal transactions were extracted from TS-2000 of
the Korea Listed Company Association, and data related to stock price were
extracted from KISVALUE-III of National Information and Credit Evaluation In-
formation Service Co., Ltd. STATA 12.0 was used as the statistical package for
panel analysis.
Results: In the pharmaceutical firms, the influence of the R&D intensity with
regard to Tobin’s q was found to be positive. However, only the R&D expenditure
intensities of previous years 2 and 5 (te2 and te5, respectively) were statisti-
cally significant (p < 0.1), whereas those of previous years 1, 3, and 4 years (te1,
te3, and te4, respectively) were not statistically significant.
Conclusion: R&D investment not only affects the enterprise value but is also
evaluated as an investment activity that raises the long-term enterprise value.
The research findings will serve as valuable data to understand the enterprise
value of the Korea pharmaceutical industry and to strengthen reform measures.
Not only should new drug development be made, but also investment and support
should be provided according to the specific factors suitable to improve the
competitiveness of each company, such as generic, incrementally modified
drugs, and biosimilar products.uted under the terms of the Creative Commons Attribution-NonCommercial-No Derivative
.org/licenses/by-nc-nd/4.0) which permits non-commercial use, distribution, and repro-
ginal author and source are credited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
242 M. Lee, M. Choi1. Introduction
Pharmaceutical companies tend to develop new drugs
to treat new diseases through research and development
(R&D) investment to create a next-generation profit
source, or develop relatively cost-effective drugs to
maximize enterprise value. R&D investment has been
relatively insufficient despite constant industry growth,
whereas the percentage of selling, general, and admin-
istrative expenses including sales promotion costs has
been high. Going forward, the government’s reform
policies will kick into high gear in the pharmaceutical
industry. These have established in the domestic market
relatively high generic medicine costs compared with
those of advanced countries and unfair competition such
as negative rebates. It can be said that a bond of sym-
pathy has developed between the pharmaceutical in-
dustry and the government around the need to support
R&D investment to promote the industry as a future
growth engine.
Studies that have empirically analyzed R&D in-
vestment in the pharmaceutical industry largely clarify
factors that have positive relevance for R&D invest-
ment. Grabowski and Vernon [1] determined that,
among pharmaceutical companies, there is a positive
relevance between a firm’s internal cash flow and R&D
costs. Vernon [2] studied firms exposed to the U.S.
pharmaceutical pricing policy and revealed that there
is a positive relevance between the former term’s in-
ternal cash flow and the current term’s expected returns
as R&D determinants. Lee and Lee [3] used explana-
tory variables such as R&D intensity and accounting
profit rate (BIS) ratio, targeting 63 pharmaceutical
companies using data from 2001 to 2006, and analyzed
their effects on corporate performance in a time-lag
model. They reported that R&D cost intensity a year
ago had a positive influence on the current term’s ratio
of ordinary profit, whereas R&D expenditures of pre-
vious years 2 and 3 had a negative influence on that
ratio. This was presumably due to the research in-
vestment characteristics for new drug developments
(long-term investment), and structural characteristics
of R&D activities that focus on incrementally modified
drugs and generic medicine.
A firm’s R&D activities are gradually taking up a
significant part of its investment activities related to the
enhancement of enterprise value [4]. Thus, analysis of
R&D activities and enterprise value is an ongoing
research topic. There are many studies that analyze the
relevance between R&D expenditures and the present or
future enterprise value, which can be summarized
mainly into three perspectives. First, there is the
perspective of a decrease in enterprise value. It argues
that R&D investment has relatively higher risk than real
investment due to a higher probability of failure, and
thus, if investors make investments with a short-termrequirement in the stock market, R&D investment
leads to a decline in stock prices. Moreover, even if an
R&D investment turns out to be successful, it takes quite
a long time for the outcome to come to fruition, and only
investments that satisfy certain capitalization re-
quirements are processed as assets. Other research costs
(in Korea), or the total R&D costs (in the United States),
are processed as expenses, which may reduce the profits
for the term. Studies that analyzed the cases of actual
R&D processed as assets or costs [5] presented an
empirical analysis result showing that the processed
research costs may negatively affect enterprise value.
Some point out that market response to R&D investment
may vary according to periods. In the United States, it
was reported that the influence of R&D investment on
enterprise value in the 1980s was insignificant or
negative [6]. Second, it is the perspective of an increase
in enterprise value. Although an R&D investment may
have a negative effect on short-term accounting profits
or stock price increases, in the long-term such invest-
ment enables new technologies, increases productivity,
and reduces costs. At the same time, increased sales
from new and improved products enhance profitability.
However, R&D projects have a high uncertainty and do
not lead directly to profits. Nevertheless, these can in-
crease future expected cash flow by securing core
corporate competences and enhancing competitiveness,
and thus, they positively affect enterprise value [7]. As a
result, firms making R&D investments can be consid-
ered firms that make strategic investments for the long
term to increase enterprise value. Therefore, the domi-
nant argument is that R&D investment positively affects
enterprise value, such as a stock price response showing
a positive excess earning rate due to disclosure or in-
crease of an R&D investment, or an increase in the long-
term enterprise value [7e10].
If the outcome of R&D activities influences enter-
prise value, the degree of its effect on enterprise value
may vary according to the degree or characteristics of
the factors that influence R&D activities. Empirical
studies suggest that the relationship between R&D in-
vestment and enterprise value may be influenced by
corporate and financial characteristics or financial
environment. Doukas and Switzer [11] presented evi-
dence that firms with higher industrial concentration
show greater stock price response when R&D invest-
ment is disclosed. Chauvin and Hirschey [12] and
Connolly and Hirschey [9] argued that the greater the
business scale, the greater the effect of R&D invest-
ment. Hall and Oriani [13] suggested that lower
ownership concentration showed more positive market
response to R&D investment in France, Germany, and
Italy. Franzen and Radhakrishnan [14] pointed out that
the information effect of R&D activities may be re-
flected differently on the market value of profitable
firms versus unprofitable firms, and stated that
Table 1. Annual distribution of sample firms.
Year No. of firms Percentage Cumulative
2000 14 2.19 2.19
2001 19 2.97 5.16
2002 30 4.69 9.84
2003 34 5.31 15.16
2004 36 5.63 20.78
2005 43 6.72 27.50
2006 46 7.19 34.69
2007 52 8.13 42.81
2008 61 9.53 52.34
2009 68 10.63 62.97
2010 76 11.88 74.84
2011 80 12.50 87.34
2012 81 12.66 100.00
Time-lag effect of R&D investment 243disclosure of R&D investment contents may be impor-
tant for the effect of the R&D investment. Hillier et al
[15] comprehensively analyzed the corporate charac-
teristic variables that had been considered in previous
studies. The result showed that business scale, growth,
and market share had a positive influence on enterprise
value. By contrast, free cash flow, external capital
dependence, labor intensity, and capital intensity were
proven to have a negative effect on enterprise value. In
particular, more free cash flow may lead to a higher
probability of implementing investment projects with
net present value (NPV) of 0 or below (i.e., NPV < 0) in
the view of Jensen [16], which is negative for the en-
terprise value creation. Moreover, R&D investment
projects originally have high information asymmetry,
and thus, higher external capital dependence leading to
a negative effect on enterprise value. These results,
however, cannot be generalized for all firms in terms of
the degree of enterprise value effect from R&D ex-
penditures, but they do provide evidence that multiple
variables have influence on the effect.
It analyzes the influence of the R&D investment of
pharmaceutical companies on enterprise value and
evaluates the influential factors identified through anal-
ysis and examines positive promotion plans.2. Materials and methods
2.1. Data sources
The period of the empirical analysis is from 2000 to
2012, considering the period after the influence of the
financial crisis. The targeted firms for analysis are those
listed on the stock exchange, and they are all of firm
level. Financial statements and comments in general and
internal transactions were extracted from TS-2000 of the
Korea Listed Company Association, and data related to
stock price are extracted from KISVALUE-III of Na-
tional Information and Credit Evaluation Information
Service Co., Ltd. STATA 12.0 was used for panel
analysis. While analyzing data on R&D investment,
there were issues of omitted records, inconsistency, and
failure of reflected changes in the TS-2000 and
KISVALUE-III databases despite the fact that accuracy
of R&D cost-related data was extremely important.
Thus, this study collected data from the Data Analysis,
Retrieval, and Transfer system of the Financial Super-
visory Service.
Ultimately, 640 firm-year data of 81 firms were
included in the sample. Unbalanced panel data with
different data-inclusion periods of variables listed in
Table 1 could be obtained according to the availability
of data. Considering the characteristics of R&D in the
pharmaceutical industry, we expanded the lagged vari-
able to 6 years including the current term. The data used
in this study are panel data with characteristics of both
cross-sectional and time series data, and therefore,require the application of an appropriate analysis
method. That is, in linear regression models for panel
data, the estimation scheme varies depending on
whether there is the error term within the fixed effect or
random effect model.
The data for this study are not randomly extracted
from the population of the listed market and can be the
population itself with the exclusion of certain data, and
therefore, they can be estimated using the fixed effect
model. It was intuitively decided that the characteristics
of panel entities must be taken into account considering
that the sample is the listed market. Thus, the F test was
used to conduct the goodness-of-fit test for the fixed
effect model. The result showed that the p value is
smaller than 0.01 in the entire model, indicating that
there are fixed entity characteristics. In other words, the
fixed effect model was more suitable than OLS. More-
over, the null hypothesis that the corporate characteris-
tics variable of the individual effect does not exist was
rejected when the Hausman test was conducted. There-
fore, the result coincided with the knowledge that the
fixed effect model is a better fit than the random effect
model.
2.2. Definition and measurement of variables
Tobin’s q: The majority of studies use Tobin’s q to
proxy for firm value. Consistent with Cummins et al
[17], we define Tobin’s q as the market value divided
by the book value of assets.
R&D intensity: This was measured based on research
costs and ordinary development costs on income
measurement. R&D intensity was used as a depen-
dent variable to eliminate errors due to relative dif-
ference according to sales of each firm [18].
Growth: This study also assumed that firms with high
growth will be more active in R&D investment, and
used the rate of sales increase as the proxy variable
for growth.
Figure 1. Research model.
244 M. Lee, M. ChoiLiquidity: Firms tend to prefer internal financing to
external financing due to information asymmetry.
This study used current ratio as the proxy variable for
liquidity.
Leverage: Making strategic decisions such as R&D
investment may be restricted by financial resources
available in the company, and thus, it is necessary to
examine the capacity of external financing of the
company [19]. This study used debt ratio.
Major shareholders: One major shareholder refers to
the shareholder with the most shares owned by
himself or herself as well as his or her family, rela-
tives, and affiliate persons. The major shareholder
information announced in the distribution of share-
holding size in the business report in the relevant
settlement term was used to determine the share-
holding ratio of major shareholders.
Foreign ownership: In the view of the efficient
monitoring hypothesis, institutional and foreign in-
vestors are important agents and external control
mechanisms that monitor the business activities ofTable 2. Descriptive statistics.
Variable Observed Mean Sta
q 640.00 4.89
RD 640.00 6.95
RDte1 589.00 6.31
RDte2 534.00 5.72
RDte3 477.00 5.42
RDte4 422.00 5.05
RDte5 370.00 4.60
SG 640.00 10.51
LIQ 640.00 362.91
LEV 640.00 61.14
OWN 640.00 37.18
FOR 640.00 5.91
SIZE 640.00 7.98
YEAR 640.00 1.01
FORZ shareholding ratio of foreigners; LEVZ stability; LIQZ liquidity; OW
SG Z growth; SIZE Z firm size; YEAR Z firm age.the management as outside shareholders, and they
influence corporate innovation in the long-term in-
vestment view [20]. Therefore, this study used the
data of the shareholding ratio of foreigners of end-of-
the-term ordinary shares.
Business scale: If the scale is huge, there are rela-
tively more resources, thereby increasing the capacity
to endure investments with long payback periods
such as R&D [21]. Therefore, business scale was
controlled in this study
Firm age: The longer the term after the firm was
established and listed, the higher the possibility that
investment decisions will be long term. In this study,
the years listed (years passed after the firm was lis-
ted) was controlled instead of years established.2.3. Research model
We applied the research model (Fig. 1) for the
empirical analysis as follows:
QitZaþ b1RDit þ b1RDit1þ b2RDit2þ b3RDit3
þ b4RDit4þ b5RDit5þ b6SGit þ b7LIQit
þ b8LEVit þ b9OWNit þ b10FORit þ b11SIZEit
þ b12YEARit þ mi þ εit
where mi is an individual-specific effect that is not
observable and that is not changeable with lapse of time
and εit is an ordinary error term. Details of the other
variables are provided in the “Results” section.3. Results
Table 2 shows the descriptive statistics of key vari-
ables of all firms used in the empirical analysis. The
characteristics of probability distribution and the outliersndard deviation Minimum Maximum
13.34 1.53 112.36
9.92 0.14 99.07
8.65 0.14 86.69
7.50 0.14 63.90
7.02 0.14 63.90
6.47 0.19 63.90
5.48 0.12 41.30
25.76 48.72 501.81
289.60 35.20 2,269.89
77.65 0.00 1,549.72
14.67 2.31 79.50
10.84 0.00 57.79
0.43 6.98 9.24
0.44 0.00 1.71
NZ shareholding ratio of major shareholders; RDZ R&D investment;
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Time-lag effect of R&D investment 245of key variables are as follows. The dependent variable
of Tobin’s q (q) appeared to be approximately 4.89%,
and the maximum and minimum values show that there
are considerable gaps among firms.
The average of the variables related to R&D invest-
ment was highest for the RD with 6.95, whereas that for
RDte1 was 6.31, RDte2 was 5.72, RDte3 was 5.42, RDte4
was 5.05, and RDte5 was 4.60. It can be inferred that
R&D investment increases every year. However, the
average of variables related to control variables was the
highest for liquidity (LIQ) with 362.91, and maximum
and minimum values show that there are considerable
gaps among firms. Growth (SG), stability (LEV),
shareholding ratio of major shareholders (OWN),
shareholding ratio of foreigners (FOR), firm size (SIZE),
and firm age (YEAR), which, in this study, were
considered as control variables and factors that may
influence enterprise value, turned out not to have a great
standard deviation compared with the average, and
therefore, appeared not to have a significant problem in
normal distribution.
Table 3 presents the Pearson correlation coefficient to
verify the multicollinearity status and correlation among
explanatory variables. According to the analysis of the
correlation between R&D intensity and the controlled
variables, most of the R&D intensity lagged variables
showed positive correlation; in particular, the R&D in-
tensity of the current and previous terms showed very
high positive correlation. The results are presented in
Table 4.
In the pharmaceutical firms, the influence of the R&D
intensity with regard to Tobin’s q was found to be
positive. However, only the R&D expenditure in-
tensities of previous years 2 and 5 (te2 and te5,
respectively) were statistically significant (p < 0.1),
whereas those of the previous years 1, 3, and 4 (te1,
te3, and te4, respectively) were not statistically sig-
nificant. In terms of the regression coefficient of other
controlled variables, it can be said that the enterprise
value was higher when the current ratio (LIQ) was
higherdor the enterprise value was higher when the
business scale (SIZE) was smaller. It can be inferred that
when listed for more years (YEAR), the enterprise value
is rated higher.T
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V4. Discussion
This study verified whether R&D investment in-
fluences enterprise value through the time-lag effect.
TS-2000 and KISVALUE-III was used for the data
analysis in this study. This study analyzed the influ-
ence of R&D investment on enterprise value at
pharmaceutical companies. According to Eberhart
et al [22], an increase in R&D investment significantly
increases business performance. Jain and Kini [23]
stated that there is a significant positive relationship
Table 4. Results.
Coefficient SE Coefficient SE Coefficient SE Coefficient SE Coefficient SE Coefficient SE Coefficient SE
RD 0.0721 0.0736 0.0748 0.177
RDte1 0.0756 0.0819 0.0279 0.184
RDte2 0.0516 0.0930 0.335z 0.192
RDte3 0.0444 0.107 0.191 0.160
RDte4 0.0787 0.126 0.188 0.171
RDte5 0.418
y 0.188 0.334z 0.203
SG 0.00627 0.0122 0.00544 0.0211 0.00654 0.0222 0.00503 0.0233 9.24  103 0.0248 0.00686 0.0264 0.00135 0.0266
LIQ 0.00180 0.00162 0.00142 0.00180 0.00127 0.00200 0.00077 0.00218 0.00126 0.00242 0.00434 0.00263 0.0055y 0.00278
LEV 0.00340 0.00463 0.00379 0.00478 0.00855 0.0164 0.0112 0.0180 0.00472 0.0199 0.00873 0.0210 0.00296 0.0213
OWN 0.0261 0.0506 0.0404 0.0580 0.0317 0.0628 0.0203 0.0701 0.0362 0.0778 0.0727 0.0829 0.0563 0.0827
FOR 0.00638 0.0461 0.00347 0.0463 0.0068 0.0488 0.00344 0.0512 0.0168 0.0539 0.0270 0.0549 0.0190 0.0548
SIZE 10.92* 2.829 13.39* 3.107 15.01* 3.435 15.30* 3.829 13.07* 4.181 11.71y 4.692 14.63* 4.817
YEAR 14.37* 2.073 20.73* 2.881 25.11* 3.706 24.97* 4.713 24.10* 5.840 20.82* 7.129 7.129 7.150
Constant 76.32* 21.54 88.33* 23.10 95.72* 25.11 97.66* 27.50 83.10* 29.80 75.02y 33.07 93.81* 34.03
Adjusted R2 0.0612 0.0615 0.0727 0.115 0.153 0.165 0.151
Observed 640 589 534 477 422 370 370
ID 81 81 76 72 68 62 62
FOR Z shareholding ratio of foreigners; LEV Z stability; LIQ Z liquidity; OWN Z shareholding ratio of major shareholders; RD Z R&D investment; SE Z standard error; SG Z growth; SIZE Z firm size;
YEAR Z firm age. *p < 0.01, yp < 0.05, zp < 0.1.
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Time-lag effect of R&D investment 247between investment in equipment and machinery and
business performance. Compared with the findings of
previous studies, this study focused on pharmaceutical
companies publicly listed between 2000 and 2012, and
found that R&D investment increased enterprise
value. This analysis identified conditions for R&D
investment that translate into corporate performance,
and revealed that R&D investment has a positive
impact on enterprise value, which is a comprehensive
value index for any company. It can be inferred that
R&D investment not only affects the enterprise value
but is also evaluated as an investment activity that
raises the long-term enterprise value. In addition, even
if this influence is led by firms with a high R&D in-
vestment ratio and the influence on the enterprise
value is offset by firms that do not invest in R&D at
all, it can be understood that R&D investment in-
creases the enterprise.
The results of this research are assumed to reflect the
characteristics (long-term investment) of new drug
development in the Korean pharmaceutical industry
with poor sales, structural characteristics of generic
drugs, and modified drug-centered R&D activities.
However, as it is anticipated that there will be a sig-
nificant systematic difference, it appears that this situa-
tion would not be applied in the future. The reason is
that for systematic changes, such as the implementation
of the positive list system of pharmaceuticals where it is
determined whether the insurance payment would be
made according to the economic evaluation of the
pharmaceuticals, the enhancement of the patent right
according to free trade agreements including the United
StateseKorea Free Trade Agreement, etc. would be a
significant threat.
It is believed that, in the future, R&D-centered
pharmaceutical firms focusing on the development of
modified new drugs and new molecular entities that are
competitive in the global market would achieve better
financial performance than they currently do. The
future growth of the Korean pharmaceutical industry
would be possible only with the combination of the
management of firms based on the strategic R&D in-
vestment, strategic thoughts of chief executive officers,
strategic partnerships with other firms, and systematic
support (tax system, medicine price system, etc.) by the
government. Thus, R&D investment is a significant
activity that would positively contribute to profit crea-
tion in the future: to secure competitive advantage in
the health medical field in the future, it would be
necessary to take a strategic approach to current R&D
investment.
4.1. Practical implications
There is a need for strategies to develop a portfolio
of products that would improve the competitiveness of
the relevant company rather than a consistent strategy
of new drug development. Recently, many companiesconsidered new drug development as the only way to
secure competitiveness in the tough conditions pre-
vailing in the pharmaceutical industry. However,
developing new drugs carries great risk, requiring high
investment and time. Therefore, not only should new
drug development be made, but also investment and
support should be provided according to the specific
factors suitable to improve the competitiveness of each
company, such as generic, incrementally modified
drugs, and biosimilar products. Further, it is necessary
to support the generic industry, to improve access to
drugs. Using generic drugs to reduce medical costs is a
global trend, and considering the case of Israel’s
pharmaceutical company Teva as well as India’s policy
of developing the generic industry, fostering the
generic industry should be viewed negatively. There-
fore, there is a need for strategies that are suitable to
improve the competitiveness and characteristics of
each company.Conflicts of interest
All contributing authors declare no conflicts of
interest.
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